Traditional PICC Technology

HydroPICC Technology

Access Vascular: Reinventing Venous Access

Access Vascular is developing a platform of venous access devices using our novel bulk hydrophilic biomaterial technology which inhibits the accumulation of blood components otherwise known as thrombus. Thrombus formation restricts flow through and around the device, which adversely affects infusion and aspiration, often requiring the use of expensive thrombolytic medications or even device replacement to resolve the blockage. Our technology is less likely to be recognized by the body as a foreign material and as a result, may not trigger the body’s thrombotic response at the same rate as current devices. The HydroPICC™ is the first in our suite of venous access devices and studies show a significant reduction in platelet count with the HydroPICC versus current devices.

Our novel bulk-hydrophilic biomaterial platform changes everything.

Eliminates Thrombosis

Reduces Complications and Costs

Improves Patient Outcomes

Traditional Technology vs. HydroPICC™ Technology

Current Polymer Technology:  Seconds after a catheter is placed into the bloodstream, blood proteins (fibrinogen and collagen) and host cells (platelets) begin to deposit on the device surface. Thrombus formation restricts flow through and around the device and can become friable and dislodge into the bloodstream which has resulted in deep vein thrombosis and pulmonary embolism in several major clinical studies.

HydroPICC™: In testing, the HydroPICC™ has shown on average a 97% reduction of thrombus when compared to controls. These results represent the potential for our technology to improve venous access procedures in a way that no existing solution has done. Greatly reducing thrombosis as a problem will have a significant and profound impact on patients’ lives.

Traditional Technology vs. HydroPICC™ Technology

Current Polymer Technology:  Seconds after a catheter is placed into the bloodstream, blood proteins (fibrinogen and collagen) and host cells (platelets) begin to deposit on the device surface. Thrombus formation restricts flow through and around the device and can become friable and dislodge into the bloodstream which has resulted in deep vein thrombosis and pulmonary embolism in several major clinical studies.

HydroPICC™: In testing, the HydroPICC™ has shown on average a 97% reduction of thrombus when compared to controls. These results represent the potential for our technology to improve venous access procedures in a way that no existing solution has done. Greatly reducing thrombosis as a problem will have a significant and profound impact on patients’ lives.

Venous Access Solutions

Patient Experience: Complications seen with PICC lines lengthen hospital stays and increase patient morbidity and mortality. Eliminating the potential for complications and extended hospital stay will improve patient experience and reduce costs. Our solutions are predicted to decrease morbidity, shorten hospital stays, advance treatment and minimize pain.

Legacy System Integration: Our HydroPICC™ device will be placed using the same procedures as current technology, so there will be no procedural changes or need for retraining.

Consumer-Centric Approach: Complications with current catheters delay care, compromise outcomes and increase costs. Issues with PICC lines are common, in fact 25% of PICC lines become occluded. Premature device replacement and hospital acquired infections impose a major burden on the healthcare system.